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Abstract
Background:  Human immunodeficiency virus (HIV) infection continues to increase at  alarming
rates in drug abusers, especially in women. Drugs of abuse can cause  long-lasting damage to the
brain and HIV infection frequently leads to a  dementing illness.To determine how these drugs
interact with HIV to cause CNS  damage, we used an in vitro human neuronal culture characterized
for the  presence of dopaminergic receptors, transporters and estrogen receptors. We
determined the combined effects of dopaminergic drugs, methamphetamine, or  cocaine with
neurotoxic HIV proteins, gp120 and Tat.
Results:  Acute exposure to these substances resulted in synergistic neurotoxic  responses as
measured by changes in mitochondrial membrane potential and  neuronal cell death. Neurotoxicity
occurred in a sub-population of neurons.  Importantly, the presence of 17beta-estradiol prevented
these synergistic  neurotoxicities and the neuroprotective effects were partly mediated by
estrogen receptors.
Conclusion:  Our observations suggest that methamphetamine and cocaine may affect the  course
of HIV dementia, and additionally suggest that estrogens modify the  HIV-drug interactions.
Introduction
HIV infection is currently the third leading cause of
death in women ages  25-44 years [1] and manifestations
of HIV infection show  important gender-dependent dif-
ferences. Women frequently develop menstrual  abnor-
malities with amenorrhea, and manifestations of AIDS
occur at higher CD4  counts and lower viral load as com-
pared to men [2].  Plasma estradiol levels are also lower
in HIV-infected women [ 3]. It remains unclear if demen-
tia associated with HIV infection occurs  more frequently
in women than men. A large multicenter European study
showed  that women were twice as likely to develop HIV
dementia compared to men [4]; however, another study
failed to confirm these differences  [5].
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Drug abuse accounts for nearly half of the HIV infections
in women in United  States[1], however, the effect of drug
abuse on  incidence, rate of progression or severity of
HIV dementia is not entirely  clear. Although no major
differences were noted in cognitive functioning  amongst
HIV-infected asymptomatics with or without a history of
drug abuse  [6], a subsequent study showed that a history
of  injection drug use and presentation with prominent
psychomotor slowing was  associated with more rapid
neurologic progression [7].  Other neuropathological
studies show marked sever ity of HIV encephalitis in
drug abusers [8] particularly involving loss of  dopamin-
ergic neurons [9]. Long term methamphetamine use  has
also been associated with neuronal damage as deter-
mined by magnetic  resonance spectroscopy brain imag-
ing studies [10].  Autopsy studies also confirm injury to
dopaminergic neurons in cocaine as well  or metham-
phetamine abusers [11, 12 ]. Interestingly, some investi-
gators have proposed the use of psychostimulants  in the
treatment of HIV dementia [13], however the  effects of
these drugs on cerebral function in the setting of HIV in-
fection has  not been well studied.
Table 1 
Antigen Primary Dilution Antibody Secondary Specificity & 
antibodies/ Source antibodies/antisera Subcellular distribution
antisera (dilutions)
Estrogen Mouse 1:10 Chemicon Goat anti-mouse  IgG Neurons and astrocytes /
receptor IgG1  (MAB428) (H+L)conjugated to  Cy3 Punctate nuclear and
(ER) monoclonal (1:250) perinuclear  distribution
Dopamine Rabbit 1:1000 Chemicon • Goat  anti-rabbit IgG Neuronal processes and cell
(DA) IgG (AB122S) DTAF (1:500) or body
polyclonal • Goat anti-rabbit IgG Cytoplasmic  distribution
Cy3  (1:250)
Dopamine Rat 1:100 Chemicon Goat anti-rat  IgG Neuronal processes and cell
transporter Ig type (MAB369) conjugated to biotin- body; astrocytes
(DAT) monoclonal avidin-Cy2 (1:250) Cell  membrane
Dopamine Rabbit 1:100 Chemicon Goat  anti-rabbit IgG Neurons and astrocytes;
D1A polyclonal (AB1784P) DTAF (1:500) punctate distribution
receptor
Dopamine Rabbit 1:500 Chemicon Goat anti  rabbit IgG Neuronal processes and cell
D2 polyclonal (AB1558) DTAF (1:500) bodies: perinuclear
receptor distribution, astrocytes,
microglia
Co-localization
Combined • Goat anti-rabbit IgG Colocalized in  neurons
• DA + as above as above as above DTAF + and/or astrocytes
• ER • Goat anti-mouse
Cy3
Combined • Goat anti-rabbit IgG Colocalized  in
• DA + as above as above as above Cy3 subpopulations of neurons
• DAT • Goat anti-rat IgG and/or  astrocytes
biotin-avidin Cy2
Combined as above as above as above • Goat  anti-rabbit IgG Colocalized in
• D1A + DTAF (1:500) subpopulations of  neurons
• ER • Goat anti-mouse and/or  astrocytes
Cy3  (1:250)
Combined as above as above as above • Goat  anti-rabbit IgG Colocalized in
• D2 + DTAF (1:500) subpopulations of  neurons
• ER • Goat anti-mouse and/or  astrocytes and
Cy3  (1:250) microglia
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HIV proteins gp120 and Tat have been implicated in the
neuropathogenesis of  HIV dementia. Both proteins are
released from HIV infected cells and are  present in the
brains of HIV infected patients with dementia or en-
cephalitis  [14]. Recent studies from our laboratory have
shown that  these proteins cause synergistic neurotoxic-
ity that involves excitatory amino  acid receptors and ox-
idative pathways [15].
Estrogen deficiency has been implicated as a risk factor
in the development  of several neurodegenerative diseas-
es [16,17,18] and estrogen replacement may  result in im-
provement of cognitive function [19]. The  mechanisms
by which estrogens protect neurons is currently under
intense  investigation and may involve, receptor-mediat-
ed mechanisms or  non-receptor-mediated antioxidative
effects. For these reasons, we assessed the  combined ef-
fects of HIV proteins and drugs of abuse, methampheta-
mine and  cocaine on neuronal function and determined
to what extent estrogen may protect  against these neu-
rotoxic substances.
Results
Detection of estrogen receptors and dopaminergic neu-
rons in human  fetal brain cells
Estrogen receptors were localized in the neuronal cul-
tures by immunostaining  and by mRNA analysis by RT-
PCR. We found that 5-10% cells immunostained for  es-
trogen receptors. Estrogen receptors could be localized
in both neurons and  astrocytes (Figures 1A, B and 2D-F
). The immunostaining was noted in the cytoplasm and
nucleus of these cells.  mRNA for estrogen receptor-α but
not estrogen receptor-β could be  detected in these cul-
tures (Figure 3). Dopaminergic  neurons were detected
by immunostaining for dopamine and dopamine trans-
porter  which could be co-localized in nearly 60% neu-
rons (Table 1, Figures 2A-C) as well as dopamine
receptors: D1A (50%  cells) and D2 (40% cells) (Figures
2E, and 2F). Estrogen receptor colocalized with cells
staining for dopamine  (Figure 1A) as well as D1A and D2
receptor containing  neurons (Figures 2E and 2F).
Blocking of neurotoxicity of supernatants from HIV infect-
ed  monocytes with antisera to gp120 and Tat
Cell culture supernatants from HIV infected monocytic
cells were collected  periodically and analyzed for their
neurotoxic potential. Maximum neurotoxicity  was noted
at two weeks post infection (Figure 4A).  Complete oblit-
eration of neurotoxicity was noted when the superna-
tants were  immunoabsorbed against antisera to gp120
and Tat (Figure  4B). However, when immunoabsorbed
against each of the antisera alone,  the effect on neuro-
toxicity of the culture supernatants was not significant
(not shown).
Neurotoxicity of HIV proteins with methamphetamine or 
cocaine
To determine the synergistic neurotoxic properties of the
viral proteins and  drugs of abuse, we initially conducted
time and dose response curves for each  compound indi-
vidually and then in combination of one another. We de-
termined  that dosages for causing neuronal cell death or
changes in mitochondrial  potential paralleled one an-
other, however changes in mitochondrial potential  could
be seen as early as 4-8 hours (Figure 5),  significant cell
death occurred at 16 hrs post treatment. No significant
toxicity was noted with Tat <80 nM, gp120 <40 pM, or
Tat (40 nM) +  gp120 (30 pM) (Figure 5).
To determine the specificity of Tat action, we used a two
Tat deletion  mutants (Tat∆31-61 and Tat∆48-56). No
changes in neuronal cell death  were noted at maximal
concentrations of Tat∆31-61 tested (500 nM) and  partial
obliteration of neurotoxicity was noted with Tat∆48-56
(Figure  6). These observations are consistent with our
previous  experience with synthetic Tat peptides demon-
strating that Tat31-61 contains the  neurotoxic epitope
[20]. To determine the specificity of  gp120 action we
used a non-specific glycoprotein α2-HS glycoprotein. No
Figure 1
Immuonolocalization of estrogen receptor and
dopamine. Mixed  neuronal cultures were immunostained
as described in methods. (A)  co-localization of dopamine
(green) and estrogen receptor(ER) (red) in neurons.  Dual
staining cells appear yellow. (B) Immunostaining for
dopamine. (C)  immunostaining for ER. Scale bar in A = 30
µm and the scale bar in B and C  = 50 µm.
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neurotoxicity was detected at the highest concentrations
tested (1 µM).
Similarly, no significant neurotoxicity was noted with
methamphetamine  <500 µM (Figure 5A). In addition,
all  concentrations of cocaine tested were non-toxic by
these assays. The maximal  concentration tested was 16
uM. 40 nM Tat + 30 pM gp120 with cocaine (1.6 or 16
µM) or methamphetamine (250 or 500 µM) produced
significant (P <  0.05) neuronal cell death (Figure 5A and
5B) and decreases in mitochondrial potential in each
case (Figure 5C). When 80 nM Tat was combined with ei-
ther 30 pM gp120, 500  µM methamphetamine or 1.6 µM
cocaine, significant decreases in  mitochondrial potential
(P < 0.05) were observed demonstrating a  synergistic
neurotoxic response between the viral proteins and
drugs of abuse.  The synergism for both methampheta-
mine and cocaine showed a steep dose response  suggest-
ing an "all or none" phenomenon (Figure 5).
Protection against HIV protein-induced mitochondrial tox-
icity by  17β-estradiol
We determined the ability of 17β-estradiol to protect
against the  synergistic neurotoxicity induced by the viral
proteins alone or in combination  with cocaine or meth-
amphetamine. Nearly complete attenuation of neuronal
cell  death induced by Tat+gp120 was noted in a concen-
tration dependent manner  (Figure 7). 1 nM 17β-estradiol
could also protect  against the combined synergistic neu-
rotoxicity of the viral proteins (Tat 40  nM+gp120 30
Figure 2
Immuonolocalization of dopamine and estrogen
receptors showing  immune reactivity in neuronal cultures
(95% neurons and 5%astrocytes) for A -  dopamine B -
dopamine transporter (DAT) C - dopamine and DAT D -
estrogen  receptor (ER) E - Dopamine D1A receptor with
ER F - Dopamine D2 receptor with  ER Scale bars in A&B =
25 µm, C&D = 15 µm; E&F = 25  µm.
Figure 3
Estrogen receptor mRNA in neuronal cultures. Estro-
gen  receptor-α mRNA (ER-α) was detected by RT-PCR and
Southern blotting.  Lane 1: lymphoid cells; Lane 2: human
neuronal cultures; Lane 3: monocytic  cells. ER-α is present
only in human neuronal cultures.
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pM) with cocaine (1.6 µM) or methamphetamine (500
µM)  (Figure 8). 1 nM 17β-estradiol protected against
both, changes in mitochondrial membrane potential
(Figure 8A and 8B) and neuronal cell death (Figure 8C).
However, this toxicity of higher concentration cocaine
(16  µM) could be only partially reversed by 1 nM 17β-es-
tradiol (Figure  8B). A lower concentration of 17β-estra-
diol (0.1 nM)  could also completely reverse the changes
in mitochondrial membrane potential  (Figure 8A and
8B) but not cell  death (Figure 7). To determine the
mechanism of estrogen  action, we pretreated the cells
with either ICI 182,780 (1 µM or 10  µM) or tamoxifen
(100 pM, 1 nM). We tried several different combinations
and concentrations of viral proteins and methampheta-
mine or cocaine. Although  protection with 17β-estradiol
was consistently present, in each case the  estrogen an-
tagonists failed to reverse the protective effects of  17β-
estradiol on mitochondrial membrane potential (Figure
8A and 8B). Interestingly, however, ICI 182,780, a  pro-
totypic estrogen antagonist, blocked the protective effect
of  17β-estradiol on neuronal cell death (P < 0.05) while
Figure 4
Neurotoxic factors from HIV infected cells Monocytic
cells  (THP-1) were infected with HIV-AdaM and culture
supernatants were periodically  collected, diluted 1:1 in
Locke's buffer and analyzed for neurotoxicity on  mixed
human neuronal cell cultures. (A) Maximal neurotoxicity was
noted in  supernatants 2 weeks post infection (*P < 0.05). (B)
Culture  supernatants from days 13 and 15 when immunoab-
sorbed with antisera to gp120 and  Tat show nearly com-
plete blocking of neurotoxicity. Uninfected culture
supernatants from corresponding days in both sets of experi-
ments showed <2%  neurotoxicity. Each data point repre-
sents mean ± SEM from three different  cultures.
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Figure 5
Synergistic neurotoxicity of HIV proteins, cocaine
and  methamphetamine. Human fetal neuronal cultures
were treated with HIV  proteins, gp120 and Tat alone or in
combination with varying concentrations of  either metham-
phetamine or cocaine. Cell death and mitochondrial mem-
brane  potentials were monitored, at 16 hours and 6 hours
respectively, in these  cultures as described in methods. Sub-
toxic concentrations of gp120 and Tat  synergize with meth-
amphetamine (A) and cocaine (B) in a dose responsive
manner  to cause neuronal cell death. (C) Tat (80 nM) when
combined with subtoxic  concentrations of gp120, metham-
phetamine or cocaine causes significant  decreases in mito-
chondrial membrane potential. Synergism is also noted when
the  combined subtoxic concentrations of gp120 (30 pM) +
Tat (40 nM) are  co-incubated with either methamphetamine
or cocaine. *P < 0.05,  **P < 0.005
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tamoxifen had  only a partial effect that was not signifi-
cant (Figure 8D). Both ICI 182,780 and tamoxifen alone
did not produce neurotoxicity at the  above concentra-
tions (Figure 8D).
Discussion
Although it is clear that patients with HIV infection may
develop dementia  and non-HIV infected drug abusers
develop evidence for neuronal dysfunction, it  is not
clearly established if patients exposed to both HIV and
drugs of abuse  are at increased risk for neurological
complications. In this study, we show  that HIV proteins
may synergize with drugs such as methamphetamine
Figure 6
Specificity of HIV protein neurotoxicity. Tat1-72
induced  neurotoxicity was compared with two deletion
mutants Tat∆48-56 and  Tat∆31-61. While Tat∆48-56
showed partial attenuation of  neurotoxicity, Tat∆31-61
showed complete obliteration. Similarly no  neurotoxicity
was noted when gp120 was substituted with alpha-2 HS-glyc-
oprotein  (a2-HS-gp).
Figure 7
Neuroprotection against HIV proteins with 17β-
estradiol.  17β-estradiol protects human fetal neurons
against neuronal cell death  induced by Tat+gp120 in a con-
centration dependent responsive manner. (*P < 0.05; **P <
0.005).
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Figure 8
Neuroprotection with 17β-estradiol against synergis-
tic  neurotoxic responses of HIV proteins, metham-
phetamine and cocaine.  Neuroprotective properties of
17β-estradiol were assessed using a  mitochondrial toxicity
assay (A and B) and a neuronal cell death assay (C and  D).
17β-estradiol at concentrations of >100 pM prevented mito-
chondrial  membrane potential changes caused by HIV pro-
teins combined with (A)  methamphetamine or (B) cocaine.
In each case estrogen antagonists tamoxifen and  ICI 182,780
failed to reverse the effects of 17β-estradiol.  17β-estradiol
had no neuroprotective effect (A). (C) Neuronal cell death
was prevented when concentrations of 17β-estradiol were ≥
1 nM. (D)  The neuroprotective effects of 17β-estradiol
could be partially reversed  by ICI 182,780 and tamoxifen. (*P
< 0.05)
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and cocaine  to cause neurotoxicity. These findings are
supported by recent observations  suggesting that HIV
infected drug abusers have a more severe encephalitis at
autopsy [7,8,9 ] and at least in some HIV infected drug
abusers an accelerated form of HIV  dementia may be ob-
served [21]. One possible cause of  this acceleration may
be the synergistic neurotoxic properties of HIV proteins
and the drugs of abuse. Our observations also suggest
that an acute exposure  may be sufficient to cause neuro-
toxicity. The mechanism by which these  substances syn-
ergize remains elusive. As demonstrated in these studies,
at  least in part the mechanism involves mitochondrial
dysfunction. Since both  gp120 and Tat have been shown
to cause toxicity to dopaminergic cells and  similarly
methamphetamine and cocaine also cause toxicity to
dopaminergic  systems, we characterized the dopaminer-
gic cell types and receptors in our  culture system. We
found that only a small proportion of these cells under-
went  cell death when exposed to the proteins and drugs
of abuse suggesting that  there must be another suscepti-
bility factor that characterizes these cells  which needs to
be identified.
We demonstrate that HIV proteins gp120 and Tat are im-
portant components in  supernatants of HIV infected
cells that cause neurotoxicity. This does not  exclude the
role of other substances such as cytokines and other sol-
uble  cellular products implicated in neuropathogenesis
of HIV infection. In fact  previous studies have shown
that most of these substances can be induced by HIV
proteins in uninfected monocytes and astrocytes [14].
Although further studies are necessary to determine the
relative amounts and  kinetics of HIV proteins released
from different HIV infected cells, previous  studies have
shown that both gp120 and Tat are present in the brains
of  patients with HIV dementia and encephalitis [15, 22].
Gp120 and Tat may also synergize to cause neurotoxicity
[15].
Recently, much attention has been given to the neuro-
protective properties of  estrogens for both chronic neu-
rodegenerative diseases and acute insults such as  stroke.
In vitro studies also show that estrogens can protect
against a number  of neurotoxic compounds [23]. The
mechanisms by which  estrogens protect cells can be
broadly classified into two categories, receptor  mediated
and non-receptor-mediated effects. Estrogen receptors
are widely  expressed in the brain with some regional dif-
ferences [24 ]. We initially demonstrated the presence of
estrogen receptors in the neuronal  cultures by immuno-
cytochemistry and determined their subtypes by mRNA
analysis.  We found that estrogen receptors are localized
both in neurons and astrocytes.  We also found that some
dopaminergic neurons co-expressed estrogen  receptors.
We next determined that 17β-estradiol at concentrations
that can either  be achieved physiologically or easily ob-
tained pharmacologically protected  against the com-
bined insult of HIV proteins and drug abuse. Protection
was  noted against both cell death and mitochondrial
toxicity. The protection was  specific since no protection
was noted with 17α-estradiol. In subsequent  experi-
ments we determined if this protection was mediated via
estrogen  receptors. Estrogen receptor antagonist, ICI
182,780 completely, and tamoxifen  partially reversed
the neuroprotective effects of 17β-estradiol using cell
death as an end point. However these compounds were
unable to reverse the  neuroprotective effects of estrogen
on mitochondrial potential, suggesting that  the mito-
chondrial effects of estrogen are non-receptor mediated.
Thus the toxic  effects on mitochondria and neuronal cell
survival seems to be independently  regulated. However,
it seems that 17β-estradiol can protect against both  these
effects by receptor and non-receptor mediated mecha-
nisms. These  observations are consistent with recent re-
ports showing that 17β-estradiol  interacts directly with a
subunit of mitochondrial F0F1-ATP synthase/ATPase
required for the coupling of a proton gradient across the
F0 sector of the  enzyme in the mitochondrial membrane
to ATP synthesis in the F1 sector of the  enzyme [25]. This
accounts for the antioxidant  properties of 17β-estradiol.
Due to its multiple sites of action, its wide  spectrum of
protection against multiple neurotoxic substances at eas-
ily  obtainable concentrations and the ease of adminis-
tration of estrogen, this  compound is a very attractive
candidate for consideration for therapeutic  intervention
in HIV-infected drug abusing women. Clinical trials are
now  necessary to confirm these observations. Caution
may be necessary in the use of  estrogens in this popula-
tion, because estrogens have been associated with a
small but real risk of ischemic heart disease and cerebral
infarcts [26]. Some patients with HIV infection may have
a  hypercoagulable state and may be at increased risk of
developing cerebral  infarcts [27].
We conclude that methamphetamine and cocaine may
synergize with HIV proteins  to cause neurotoxicity and
resulting in increased dysfunction in HIV infected  drug
users. Caution should also be used in the use of other
structurally and  functionally similar psychotropic drugs
in HIV infected patients. Estrogen may  be neuroprotec-
tive in this population acting through receptor and non-
receptor  mediated mechanisms.
Methods
Cultures of human brain cells
Brain specimens were obtained from human fetuses of
12-14 weeks gestational  age with consent from women
undergoing elective termination of pregnancy and  ap-
proval by the University of Kentucky Institutional Re-
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view Board. Neuronal  cultures were prepared as
described previously [20,  28]. Briefly, the cells were me-
chanically dissociated,  suspended in Opti-MEM with 5%
heat-inactivated fetal bovine serum, 0.2% N2  supple-
ment (GIBCO) and 1% antibiotic solution (penicillin G
104  units/ml, streptomycin 10 mg/ml and amphotericin
B 25 µg/ml) and plated in  flat bottom 96 well plates. The
cells were maintained in culture for at least  one month
before conducting the neurotoxicity and mitochondrial
experiments.
Immunostaining
Cells were plated and cultured on coverslips for immu-
nostaining. The media  was removed and neuronal cul-
tures were fixed for 30 minutes with Zamboni's  fixative
[29] at room temperature. Receptor  immunoreactivity
was determined using monoclonal or polyclonal antisera
as  listed in Table 1. Cells were incubated in blocking
buffer consisting of 4% casein (w/v) and 0.1% bovine se-
rum albumin (w/v) in  phosphate buffered saline (PBS)
at pH 7.4 for 30 min. Cells were then incubated  in pri-
mary antibody diluted in blocking buffer for at 24 h at
4°C.  Following three washes in PBS the cells were incu-
bated with fluorochrome  conjugated secondary antisera
diluted in blocking buffer (Table  1) for one hour at room
temperature. To determine specificity of  staining, some
cells were incubated in blocking buffer without primary
antibody. In addition, the specificity of particular anti-
bodies was further  confirmed by demonstrating appro-
priate patterns of subcellular immunoreactivity  in
positive controls, as well as the absence of immunoreac-
tivity in negative  controls. After the final wash, the cov-
erslips containing cells were air dried  in the dark and
mounted on slides with ProLong™ Antifade  mounting
media (Sakura Finitek USA, Torrence, CA). They were
maintained in the  dark and at 4°C until examined.
Combined detection of estrogen receptors and dopaminer-
gic  systems
Neuronal cultures plated on coverslips were initially
treated as described  above to detect estrogen receptors.
Cell were fixed in Zamboni's solution,  rinsed 3-fold in
PBS, and incubated with mouse anti-ERα or ERβ  mon-
oclonal antibodies (1:10 dilution) for at least 1 h at room
temperature.  Anti mouse IgG conjugated to Cy3 fluoro-
chrome (1:250 dilution, 1 h at room  temperature) was
used to visualize ER antigenicity (Jackson ImmunoRe-
search,  West Grove, PA). To detect dopamine (DA),
dopamine receptors D1A and D2, cells  were incubated in
rabbit polyclonal antibodies (see table) overnight at  4°C.
For detection of dopamine transporter (DAT) rat mono-
clonal antisera  were used. Cells were then incubated in
goat anti rabbit IgG (1:250 dilution)  conjugated to DTAF
for 1 h at room temperature. Cells were washes three
times  with PBS. After the final wash, the coverslips con-
taining cells were air dried  in the dark and coverslipped
with ProLong™ Antifade mounting  media (Sakura Fi-
nitek USA, Torrence, CA). They were maintained in the
dark and  at 4°C until examined.
The reaction was visualized using fluorescence microsco-
py (Nikon Diaphot)  and images acquired using a Spot 2
digital camera (Diagnostic Instruments,  Sterling
Heights, MI). Digital images incorporating multiple
fluorochromes (red  and green) were overlaid in Pho-
toshop 5.0 (Adobe).
RT-PCR for estrogen receptors
For each sample, we reverse transcribed 0.5 µg of total
RNA to produce  cDNA in a final reaction volume of 40
µl, containing 2.5 µM random  hexamers (Perkin Elmer,
Branchburg, NJ), 100 U MuLV Reverse Transcriptase
(Perkin Elmer), 1 mM dNTP mix (Life Technologies,
Gaithersburg, MD), 80 U  RNAsin (Promega, Madison,
WI), 5 mM MgCl2 (Life Technologies), and  1X reaction
buffer (Life Technologies). Each sample was incubated
for reverse  transcription at room temp. for 15 min, 37°C
for 2 min, 42°C for 1  hr, and 99°C for 5 min. The same
procedure was performed on samples  utilizing a reac-
tion solution without reverse transcriptase to check for
genomic contamination.
PCR amplification
We utilized well characterized RT-PCR methods to de-
termine relative changes  in gene expression at the
mRNA level. For each gene examined, we generated
standard curves of input RNA and cycle number to deter-
mine the optimum cycle  number within the linear range
for PCR amplification (data not shown); for all  genes ex-
amined, this was determined to be between 25-30 cycles.
These methods  have been validated in studies showing
that, within the optimal range of  amplification, yields of
PCR product are linear with respect to input RNA  [30].
For each gene, stock solutions were prepared containing
1.5 mM MgCl2, 1X reaction buffer, 10 µCi of 32P- dCTP
(3000 Ci/mmol)  (NEN, Boston, MA), 1 µM each primer,
and 1.5 U of Taq polymerase (Life  Technologies). For
ERα and ERβ PCR, 1.5 U of Taq Ab  (Life Technologies)
was included in each reaction. The stock solution was  al-
iquoted (49 µl/tube), and 1/30 of synthesized cDNA
(from reverse  transcription reaction) was added to each
sample tube. Samples were then  thermocycled for PCR
amplification (Hybaid, Touchdown Thermocycler, Mid-
dlesex,  United Kingdom) according to the following re-
action conditions: 1 min  95°C, 1 min 55°C, 2 min 72°C
(25-30 cycles). After  amplification, PCR products were
resolved by polyacrylamide gel  electrophoresis. The gels
were dried and the products were visualized and  quanti-
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fied using a PhosphorImager (Molecular Dynamics, Sun-
nyvale, CA).
All the oligonucleotide sequence pairs used for gene am-
plification in this  study generated PCR products of ex-
pected sizes that have been sequenced to  verify their
identities: L27A sense primer: 5'-ATGCTAACTGTC-
CAAGTCTA-3'  and antisense primer 5'-GGGAG-
CAACTCCATTCTTGT-3' (214 bp) [ 31]; ERα sense
primer 5'-AATTCTGACAATCGACGCCAG-3' and  anti-
sense primer 5'-GTGCTTCAACATTCTCCCTCCTC-
3'(344 bp) [ 32].
Infection of monocytic cells with HIV
THP-1 cells were cultured in RPMI+10% fetal bovine se-
rum and infected with  HIV-AdaM strain at an MOI of
100. The high MOI was chosen to ensure maximal  pro-
duction of viral proteins. Culture supernatants were col-
lected every four  days by half media exchange and frozen
at -80°C till used for  neurotoxicity assays. For immuno-
absorption of viral proteins, the culture  supernatants
were incubated for 60 min with protein A beads conju-
gated with  polyclonal antisera to either Tat or gp120
with constant shaking at room  temperature. Following
centrifugation, the supernatants were removed and  im-
mediately used for neurotoxicity assays.
Recombinant Tat and gp120 proteins
Recombinant Tat was prepared as described previously [
33] with minor modifications. The tat gene encoding the
first  72 amino acids were amplified from HIVBRU ob-
tained from Dr. Richard  Gaynor through the AIDS re-
pository at the NIH and inserted into an E.  coli vector
PinPoint Xa-2 (Promega). Two deletion mutants from
this  plasmid were also prepared. One by deleting the se-
quence encoding amino acids  31-61 of Tat previously
shown to contain the neurotoxic epitope [20]. Another
one was prepared by deleting the sequences 48-56  en-
coding the basic region of Tat. These constructs allowed
the expression of  the Tat proteins as a fusion protein
naturally biotinylated at the N-terminus.  The biotinylat-
ed Tat proteins were purified on a column of soft release
avidin  resin, cleaved from the fusion protein using factor
Xa and eluted from the  column followed by desalting
with a PD10 column. All purification steps  contained
dithiothreitol to prevent oxidation of the proteins. Tat
proteins  were >95% pure as determined by SDS-PAGE
followed by silver staining, and  analysis by HPLC using
a C4 column showed a single symmetrical peak. Western
blot analysis showed that these preparations contained
both monomeric and  dimeric forms of Tat1-72 but mon-
omeric form only for Tat∆31-61 and  Tat∆48-56. The
functional activity of Tat1-72 was confirmed using a
transactivation assay in HL3T1 cells containing an HIV-
1 LTR-CAT construct  [33]. gp120 from HIVSF2 was ob-
tained as a  gift from Chiron Corporation. Recombinant
gp120 was made in a chinese hamster  ovary cell line and
purification yielded a product that was 95% gp120 with
the  remainder being break down products of gp120 as
determined by western blot  analysis. The Tat and gp120
preparations contained <1 pg/ml endotoxin as  deter-
mined using a Pyrochrome Chromogenic test kit (Associ-
ates of Cape Cod  Inc., Falmouth, MA.). The Tat proteins
were stored in a lyophilized form and  gp120 as a stock
solution in water at -80°C in endotoxin-free siliconized
microfuge tubes until taken for experimentation. Tat and
gp120 were highly  susceptible to degradation and loss of
biological activity with each  freeze-thaw cycle. There-
fore, single aliquots were used for each experiment  with
the remaining solutions discarded.
Neurotoxicity Assay
At the time of experimental treatment, the culture media
was replaced with  Locke's buffer containing (in mM) 154
NaCl, 5.6 KCl, 2.3 CaCl2, 1  MgCl2, 3.6 NaHCO3, 5 glu-
cose, 5 N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (pH 7.2) and neurons were incubated with culture
supernatants from HIV infected monocytic cells, subtox-
ic concentrations of Tat (40 nM) + gp120 (30 pM), vari-
ous concentrations of methamphetamine or cocaine, or
viral proteins + methamphetamine and cocaine. To  de-
termine the specificity of action of the viral proteins,
Tat1-72 was compared  to Tat∆31-61 and Tat∆48-56 at
500 nM concentration each. Similarly,  gp120 (500 pM)
was compared to a non-specific glycoprotein α2-HS
glycoprotein (Sigma; 1 uM). Cell death in each case was
monitored by trypan  blue exclusion 15 hours later as de-
scribed previously [20 , 28]. Neuronal cell counts were
determined from five  fields at predetermined coordinate
locations. Each field was photographed,  coded and
counted. At least 200 cells were counted in each field.
Each  experiment was conducted in triplicate wells and at
least three independent  experiments were conducted
with each pharmacological agent. The means and  stand-
ard errors of the mean were calculated and data were an-
alyzed by ANOVA  with Tukey-Kramer post-hoc
comparisons. To investigate the neuroprotective  proper-
ties of estrogen, the cells were incubated with 17β-estra-
diol  (Sigma) at various concentrations followed by
exposure to the viral proteins  and/or the drugs of abuse
in Locke's buffer and cell death monitored as  described
above. Preincubation with 17β-estradiol in each case was
<5  min. To determine the mechanism of estrogen pro-
tection, the cultures were  incubated with either ICI
182,780 (100 nM) (Tocris) or tamoxifen (10 nM)  (Sig-
ma).
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Measurement of mitochondrial membrane potential activ-
ity
To determine the effect of the viral proteins on mito-
chondrial function, we  used a fluorescent dye JC-1 to
measure changes in mitochondrial membrane  potential.
Once loaded into the mitochondria, JC-1 undergoes ag-
gregate  formation in the regions of high potential. The
resulting spectral shift of the  dye can be used to detect
changes in mitochondrial activity. The green  fluorescent
JC-1 (5,5',  6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimi-
dazolylcabocyanine iodine, T-3168)  exist as a monomer
at low membrane potential. However, at higher poten-
tials,  JC-1 forms red fluorescent "J-aggregates" that ex-
hibit broad spectrum and an  emission maximum at 590
nm. Optical filters designed for fluorescein and  tetram-
ethylrhodamine were used to separately visualize the
monomer and  J-aggregate forms, respectively. Mito-
chondrial function was monitored following  treatment
with the above compounds at different concentrations
and time points.  Briefly, after experiment treatment
cells were incubated for 30 minutes at  37°C in a 5% CO2
incubator in the presence of 10 µM of the  JC-1 and then
washed in Locke's solution.
Optical measurements were acquired with excitation at
485 nm and emission at  527 nm, and 590 nm. The levels
of fluorescence at both emission wavelengths  were
quantified and ratio of measurements was assessed. The
pertinent data are  given as mean ± S.E.M. for mean op-
tical measurements. The values are  expressed as percent
of the mean control values ± S.E.M. and analyzed  using
ANOVA.
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